Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 145

1.

Impact of VKORC1, CYP4F2 and NQO1 gene variants on warfarin dose requirement in Han Chinese patients with catheter ablation for atrial fibrillation.

Li J, Yang W, Xie Z, Yu K, Chen Y, Cui K.

BMC Cardiovasc Disord. 2018 May 18;18(1):96. doi: 10.1186/s12872-018-0837-x.

2.

CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement.

Cen HJ, Zeng WT, Leng XY, Huang M, Chen X, Li JL, Huang ZY, Bi HC, Wang XD, He YL, He F, Zhou RN, Zheng QS, Zhao LZ.

Br J Clin Pharmacol. 2010 Aug;70(2):234-40. doi: 10.1111/j.1365-2125.2010.03698.x.

3.

Effect of gene polymorphims on the warfarin treatment at initial stage.

Liu J, Jiang HH, Wu DK, Zhou YX, Ye HM, Li X, Luo ZY, Guo Z, Zhang YL, Wang YC, Zhang W, Zhou HH, Wang LS.

Pharmacogenomics J. 2017 Jan;17(1):47-52. doi: 10.1038/tpj.2015.81. Epub 2015 Dec 8.

PMID:
26644206
4.

A new algorithm to predict warfarin dose from polymorphisms of CYP4F2 , CYP2C9 and VKORC1 and clinical variables: derivation in Han Chinese patients with non valvular atrial fibrillation.

Wei M, Ye F, Xie D, Zhu Y, Zhu J, Tao Y, Yu F.

Thromb Haemost. 2012 Jun;107(6):1083-91. doi: 10.1160/TH11-12-0848. Epub 2012 Apr 26.

PMID:
22534826
5.

Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients.

Liang R, Li L, Li C, Gao Y, Liu W, Hu D, Sun Y.

J Thromb Thrombolysis. 2012 Jul;34(1):120-5. doi: 10.1007/s11239-012-0725-7.

PMID:
22528326
6.

Effect of VKORC1, CYP2C9, CFP4F2, and GGCX Gene Polymorphisms on Warfarin Dose in Japanese Pediatric Patients.

Wakamiya T, Hokosaki T, Tsujimoto S, Kadota K, Nakano Y, Watanabe S, Iwamoto M, Yanagimachi M, Ito S.

Mol Diagn Ther. 2016 Aug;20(4):393-400. doi: 10.1007/s40291-016-0212-5. Erratum in: Mol Diagn Ther. 2016 Oct;20(5):501.

PMID:
27262824
7.

Warfarin dose requirements with different genotypes of CYP2C9 and VKORC1 for patients with atrial fibrillation and valve replacement.

Chen W, Wu L, Liu X, Shen Y, Liang Y, Zhu J, Tan H, Yang Y, Liu Q, Wang M, Liu L, Wang X.

Int J Clin Pharmacol Ther. 2017 Feb;55(2):126-132. doi: 10.5414/CP202494.

PMID:
27117036
8.

Influence of UDP-Glucuronosyltransferase Polymorphisms on Stable Warfarin Doses in Patients with Mechanical Cardiac Valves.

An SH, Chang BC, Lee KE, Gwak HS.

Cardiovasc Ther. 2015 Dec;33(6):324-8. doi: 10.1111/1755-5922.12147.

PMID:
26223945
9.

The impact of non-genetic and genetic factors on a stable warfarin dose in Thai patients.

Wattanachai N, Kaewmoongkun S, Pussadhamma B, Makarawate P, Wongvipaporn C, Kiatchoosakun S, Vannaprasaht S, Tassaneeyakul W.

Eur J Clin Pharmacol. 2017 Aug;73(8):973-980. doi: 10.1007/s00228-017-2265-8. Epub 2017 May 26.

10.

Influence of warfarin dose-associated genotypes on the risk of hemorrhagic complications in Chinese patients on warfarin.

Ma C, Zhang Y, Xu Q, Yang J, Zhang Y, Gao L, Xu B, Wang H, Li Y, Lu C, Yin T.

Int J Hematol. 2012 Dec;96(6):719-28. doi: 10.1007/s12185-012-1205-8. Epub 2012 Oct 27.

PMID:
23104259
11.

Plasma vitamin K concentrations depend on CYP4F2 polymorphism and influence on anticoagulation in Japanese patients with warfarin therapy.

Hirai K, Yamada Y, Hayashi H, Tanaka M, Izumiya K, Suzuki M, Yoshizawa M, Moriwaki H, Akimoto T, Tsuji D, Inoue K, Itoh K.

Thromb Res. 2015 May;135(5):861-6. doi: 10.1016/j.thromres.2015.02.019. Epub 2015 Feb 27.

PMID:
25747538
12.

[Impact of six genetic polymorphisms on Warfarin maintenance dose variation in Chinese Han population].

Lou Y, Han L, Li Y, Zhang X, Liu Z, Tang M, Yu H, Wang W, Xu J, Liu H, Li Y.

Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2014 Jun;31(3):367-71. doi: 10.3760/cma.j.issn.1003-9406.2014.03.024. Chinese.

PMID:
24928022
13.

Genetic and Non-Genetic Factors Affecting the Quality of Anticoagulation Control and Vascular Events in Atrial Fibrillation.

Park YK, Lee MJ, Kim JH, Lee JS, Park RW, Kim GM, Chung CS, Lee KH, Kim JS, Lee SY, Bang OY.

J Stroke Cerebrovasc Dis. 2017 Jun;26(6):1383-1390. doi: 10.1016/j.jstrokecerebrovasdis.2017.02.022. Epub 2017 Apr 12.

PMID:
28412319
14.

Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population.

Rusdiana T, Araki T, Nakamura T, Subarnas A, Yamamoto K.

Eur J Clin Pharmacol. 2013 Mar;69(3):395-405. doi: 10.1007/s00228-012-1356-9. Epub 2012 Aug 2.

PMID:
22855348
15.

Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population.

Krishna Kumar D, Shewade DG, Loriot MA, Beaune P, Balachander J, Sai Chandran BV, Adithan C.

Eur J Clin Pharmacol. 2014 Jan;70(1):47-56. doi: 10.1007/s00228-013-1581-x. Epub 2013 Sep 10.

PMID:
24019055
16.

Influence of CYP4F2 rs2108622 (V433M) on warfarin dose requirement in Asian patients.

Singh O, Sandanaraj E, Subramanian K, Lee LH, Chowbay B.

Drug Metab Pharmacokinet. 2011;26(2):130-6. Epub 2010 Nov 12.

17.

CYP4F2 gene polymorphism as a contributor to warfarin maintenance dose in Japanese subjects.

Nakamura K, Obayashi K, Araki T, Aomori T, Fujita Y, Okada Y, Kurabayashi M, Hasegawa A, Ohmori S, Nakamura T, Yamamoto K.

J Clin Pharm Ther. 2012 Aug;37(4):481-5. doi: 10.1111/j.1365-2710.2011.01317.x. Epub 2011 Dec 16.

PMID:
22172097
18.

Effects of NAD(P)H quinone oxidoreductase 1 polymorphisms on stable warfarin doses in Korean patients with mechanical cardiac valves.

Chung JE, Chang BC, Lee KE, Kim JH, Gwak HS.

Eur J Clin Pharmacol. 2015 Oct;71(10):1229-36. doi: 10.1007/s00228-015-1915-y. Epub 2015 Aug 11.

PMID:
26257249
19.

Effects of VKORC1 Genetic Polymorphisms on Warfarin Maintenance Dose Requirement in a Chinese Han Population.

Yan X, Yang F, Zhou H, Zhang H, Liu J, Ma K, Li Y, Zhu J, Ding J.

Med Sci Monit. 2015 Nov 19;21:3577-84.

20.

[Influence of warfarin related genes and non- genetic factors on administrative dose in Shanghai area].

Zhuang W, Wu D, Wang Z.

Zhonghua Xue Ye Xue Za Zhi. 2014 Jan;35(1):13-7. doi: 10.3760/cma.j.issn.0253-2727.2014.01.004. Chinese.

PMID:
24602724

Supplemental Content

Support Center